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Abstract 
BACKGROUND: Epilepsy is a serious neurological condition requiring sometimes lifelong pharmacological 
treatment, and continuous specialist monitoring.  
AIM: To investigate the use of Anti-Epileptic Drugs (AEDs) in epilepsy, with focus on the exposure of AEDs, 
differences and changes in prescription patterns over time; to evaluate the relation between the consumption data 
of AED and the level of epileptic morbidity for the period 2004-2016.  
STUDY DESIGN: Official data regarding the consumption of AEDs within Albania were collected retrospectively. 
Every year of the period, 2004-2016 has been considered separately. 
METHODS: The data were assembled from Health Insurance Institute (HII) in Tirana, Albania and analysed for 
the period 2004-2016. The consumption of drugs was expressed as several Defined Daily Dose (DDDs)/1000 
inhabitants/day. Also, for all the period under study 2004-2016, we analysed the data of import and domestic 
production of drugs, which represent the real consumption of drugs in the country. These data were subsequently 
involved in a comparative analysis with the utilisation data according to the HII, as well as through performing 
international comparisons of the consumption of AEDs drugs. 
RESULTS: Epilepsy morbidity data indicate that there exists a correlation statistically significant between this 
disease and the trend of consumption of AEDs. 
CONCLUSION: The present study suggests that the level of consumption for AEDs in Albania is very low when 
compared globally; with a decrease in the consumption of classic antiepileptic drugs and a parallel increase in the 
consumption of new generation drugs. 
 
 
 
 
 
Introduction 
 
Epilepsy is a group of neurological 
diseases characterised by a predisposition to 
recurrent unprovoked seizures [1], [2]. Epileptic 
seizures are episodes that can vary from brief and 
nearly undetectable to long periods of vigorous 
shaking [3]. The human brain is the source of human 
epilepsy. Although the symptoms of a seizure may 
affect any part of the body, the electrical events that 
produce the symptoms occur in the brain. The location 
of that event, how it spreads and how much of the 
brain is affected, and how long it lasts all have 
profound effects. These factors determine the 
character of a seizure and its impact on the individual. 
The cause of most cases of epilepsy is unknown, 
although some people develop epilepsy as the result 
of traumatic or vascular injury, brain tumours, 
infections of the brain, and congenital disabilities 
[3]. Epileptic seizures are the result of excessive and 
abnormal nerve cell activity in the cortex of the brain 
[4]. The mainstay treatment of epilepsy is anti-
epileptic medications, possibly for the person's entire 
life [5]. The choice of anticonvulsant is based on 
seizure type, epilepsy syndrome, other medications 
used, other health problems, and the person's age 
and lifestyle [6]. A single medication is recommended 
initially;
 
if this is not effective, switching to a single 
other medication is recommended [7], [8]. Two 
medications at once are recommended only if a single 
medication does not work [8]. 
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There are a number of medications available. 
Phenytoin, carbamazepine and valproate appear to be 
equally effective in both partial and generalised 
seizures [9], [10]. The least expensive anticonvulsant 
is phenobarbital. The World Health Organization gives 
it a first-line recommendation in the developing world, 
and it is commonly used there [11], [12]. 
Adverse effects from medications are 
reported in 10 to 90% of people, depending on how 
and from whom the data is collected [13]. Most 
adverse effects are dose-related and mild 
[13]. Despite this, treatment is often continued once 
effective because the risk of untreated epilepsy is 
believed to be greater than the risk of the medications 
[14]. 
The study aimed to assess the out-of-hospital 
AEDs use in Albania during the period 2004-2016. 
 
 
Material and Methods 
 
The data were obtained from the HII [15]. All 
data were collected for the period 2004-2016 and 
analysed. The analysis included the total number of 
prescriptions made and quantities of drugs used.  
The data about the population were obtained 
from the Institute of Statistics (INSTAT) [16]. The data 
about the consumption of drugs were expressed as 
several Defined Daily Dose (DDDs)/1000 
inhabitants/day. All drugs were classified by groups of 
Anatomic Therapeutic Chemical Classification (ATC). 
 
Data on real consumption (import and 
 domestic production) 
For all the period under study 2004-2016, 
there were collected and analysed data from the 
import and domestic production of the drugs [17], 
which represent the real consumption of drugs in the 
country. It was noted that the increase in consumption 
from one year to another was small, e.g. the 
consumption from 2012 to 2016 (i.e. 4 years) was 
increased by only 2.32%. Consequently, to obtain an 
updated study, there were chosen the data of import 
and domestic consumption only for the last three 
years, 2014, 2015, 2016, and those were involved in a 
comparative analysis with the equivalent consumption 
data according to HII. To minimise the effect of 
variations between consumption and stock inventory 
balances from one year to another, it was calculated 
and put to analysis the annual average value of the 
three chosen years (on the one hand that of the 
import and domestic consumption, and on the other 
hand that of HII). 
 
Presentation of the results and statistical 
 elaboration 
The database of HII was modified in Microsoft 
Office Excel 2007, whereas the statistical elaboration 
of the obtained results was conducted with the 
statistical package StatsDirect (version 2.7.2.). A 
descriptive statistic was used to report all data on 
drugs consumption and the results obtained were 
displayed in tabular form as well as through the 
histogram method. 
Average annual values of consumption in the 
country level and for each district were used as a 
basis to generate the overviews and the graphics that 
illustrate the trends of consumption for each class of 
drugs during the 10 years 2004-2016. The linear 
regression model was used to evaluate the trends of 
consumption of drugs relative to the time. A value of p 
≤ 0.05 was considered as significant. 
To asses, if there exists a correlation 
statistically significant between the level of 
consumption of drugs and the level of morbidity, it was 
applied the Spearman correlation (with a significance 
level of ≤ 0.05). 
 
 
Results 
 
The data were expressed as a number of 
defined daily doses per 1000 inhabitants/day 
(DDDs/1000 inhabitants/day). 
 
Figure 1: Consumption of different classes of AEDs at national level 
(DDD/1000 inhabitants/day) versus Epilepsy morbidity (cases/1000 
inhabitants) (For the new AEDs: p = 0,0421; strength (with 
significance level ≤ 0,05) = 53.6%; correlation coefficient statistically 
significant; for the classic AEDs: p = 0,1618; strength (with 
significance level ≤ 0,05) = 27.62%; correlation coefficient is not 
statistically significant). 
 
The consumption of AEDs was 1.82-2.30 
DDD/1000 inhabitants/day respectively in 2004-2016. 
The AEDs most prescribed are the classic or the old 
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generation with values of 1.77-1.69 DDD/1000 
inhabitants/day, 2014-2016. Meanwhile, the new 
generation of AEDs included in the reimbursement 
scheme is lamotrigine, gabapentin, levetiracetam and 
topiramate. Their values of consumption are 0.06-0.61 
DDD/1000 inhabitants/day. 
Epilepsy morbidity data indicate that there 
exists a correlation statistically significant between this 
disease and the trend of consumption of AEDs (P = 
0.0034), (Figure 1, and 2).  
 
Figure 2: Total consumption of AEDs at the national level 
(DDD/1000 inhabitants/day) versus Epilepsy morbidity (cases/1000 
inhabitants) 
 
 
 
Discussion 
 
Epilepsy is a frequent disorder in the western 
countries occurring in 4-8/1000 inhabitants [30]. The 
earliest effective pharmacological treatments to 
prevent epileptic seizures date in 1857, when Locock 
prescribed for the first-time potassium bromide. 
However, until 1970, there were in circulation, only a 
small number of antiepileptic drugs. Since then, the 
introduction of new antiepileptic molecules in the 
pharmaceutical market has been highly accelerated, 
to the point that some new antiepileptic drugs are 
prescribed even for pain control, psychiatric disorders 
or migraine prevention [31], [32], [33], [34].
  
 
Figure 3: Annual average value of consumption of classic AEDs: 
consumption-based on import (real consumption) [*] versus 
consumption based on HII. [*] The “Import” item includes the 
consumption based on import data as well as the consumption-
based on domestic production: this represents the factual 
consumption 
In Figure 1 and 2 can be noted an expressed 
inconsistency between the level of reported morbidity 
and the very low consumption of antiepileptic drugs. 
First of all, in some years it results that more than half 
of epileptic patients have not taken medication under 
the scheme. Secondly, there is noted refraction in the 
morbidity trend, going through a significant increase in 
2005 and a noticeable decrease in 2006-2007, which 
is difficult to explain from the medical perspective. The 
consumption reports do reflect the same trend too, but 
with slighter refraction and with a decrease in 
consumption in 2007. However, the consumption for 
this drugs class, although in low levels compared to 
the morbidity levels, seems relatively consistent and 
stable. A reason could be the fact that the main drugs 
in the treatment of this disease continue to be the 
classic antiepileptic drugs at low cost and low impact 
on the HII’s budget. As old preparations, they do not 
attire the interest of pharmaceutical companies, and 
hence, their promotion and marketing remain low. 
Another reason could be the fact that new antiepileptic 
drugs were included under the scheme only in 2009. 
 
Figure 4: Annual average value of consumption of new AEDs: 
consumption-based on import (real consumption) [*] versus 
consumption based on HII. [*] The “Import” item includes the 
consumption based on import data as well as the consumption-
based on domestic production: this represents the factual 
consumption 
 
To have a better understanding, we have 
analysed the data of consumption based on imports, 
comparing them to the analogue consumption data 
based on HII reports. 
As it can be noted in Figures 3, 4 and 5, the 
consumption of classical antiepileptic drugs is covered 
in only 57% by the scheme; the remainder of the 
patients take these drugs without a prescription from 
the family doctor. It should be considered in this case 
that such drugs are useable for other purposes apart 
from for epilepsy, whereas the HII reimburses them 
only for the treatment of different forms of epilepsy. 
For instance, sodium valproate is also reimbursed for 
the treatment of the manic phase of bipolar disorder 
and is also prescribed for the increase of pain 
tolerance for chronic pains. 
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Figure 5: Annual average value of consumption of both classes of 
AEDs: consumption-based on import (real consumption) [*] versus 
consumption based on HII 
 
On the other hand, the consumption of new 
antiepileptic drugs reported by HII consists in around 
60% of their total consumption based on import 
figures. Some of them, e.g. gabapentin, is increasingly 
indicated by therapeutic guidelines for the treatment of 
neuropathic pain. However, it is of interest the fact 
that the total value of consumption of antiepileptic 
drugs based on import data is very much approximate 
to the reported values of epileptic morbidity. 
Among the new antiepileptic drugs, the only 
one that has been part of the list since in 2004, is 
topiramate: 3.08%-5.43%, 2004-2016. Antiepileptic 
drugs of the new generation have been included in the 
list only by 2009. 
The consumption of antiepileptic drugs in 
different regions (Figure 6) remain relatively low. The 
region with the minimum consumption along the years 
is Vlora, whereas the maximum consumption is in 
Berat. 
 
Figure 6: Consumption of AEDs in different regions and at the 
national level (DDD/1000 inhabitants/day) 
 
A common feature for all regions is the 
gradual reduction of the consumption in 2006, and 
especially in 2007 (a year in which the list of 
reimbursable antiepileptic drugs was the poorest 
compared to any other year), whereas in subsequent 
years the list gets re-extended, a fact which is 
reflected also in the consumption, particularly in the 
last years of the study. 
At the national level, the consumption of 
antiepileptic drugs undergoes a slight increase (from 
1,82 DDD/1000 inhabitants/day in 2004 to 2.30 
DDD/1000 inhabitants/day in 2016). This increase in 
consumption does not reflect the evident increasing 
morbidity trend of 5.97% (3.31-5.27 cases/1000 
inhabitants during 2004-2016). In total, we note a 
decrease in the consumption of classic antiepileptic 
drugs and a simultaneous increase in the drugs of the 
new generation. The clinical trials performed report 
little evidence that supports the usage of monotherapy 
with antiepileptic drugs of the new generation or their 
usage as adjuvants in the antiepileptic treatment, 
compared to the classic antiepileptic drugs. 
Furthermore, there is no evidence indicating the 
priority of usage of an antiepileptic drug over another 
one [35], [36]. Levetiracetam, as well as the other 
similar antiepileptic drugs of the last generation such 
as gabapentin, lamotrigine, oxcarbazepine, tiagabine 
and topiramate, are recommended by international 
therapeutic guidelines to be used as drugs of first 
choice, in order to reinforce the “on” phenomena and 
the improvement phase in partial epilepsies at adults, 
resistant to previous drugs (with partial or generalized 
seizures) [36], [37], [38].
  
In general, the data obtained in the clinical 
efficacy, the security of consumption and the 
pharmacological tolerance to them, have not been 
able to demonstrate statistically significant differences 
between these drugs. As an exception, the 
comparison between new antiepileptic drugs and 
placebo has resulted in significant differences in 
favour of the new generation. However, the clinical 
trials are generally short-termed, limiting to a certain 
extent the applicability of the data obtained. New 
antiepileptic drugs used as monotherapy, may have a 
favourable efficacy-cost report in the treatment of 
patients that have incurred severe negative side 
effects from the old classic antiepileptic drugs, of 
those where the therapy with classic antiepileptic 
drugs has failed, or of those cases where the drugs of 
the old generation have been counter-indicated [39].
 
 
From the perspective of the efficacy-cost 
report, an investigation of the British Sanitary system 
published in 2005, has indicated that new antiepileptic 
drugs may be superior in patients with partial or 
generalised seizures refractory to traditional 
antiepileptic drugs [39]. 
  
Comparisons of consumption at the 
 international level  
In international comparisons, the consumption 
of antiepileptic drugs in Albania remains in very low 
values (Figure 7). The total consumption of 
antiepileptic drugs in our country in 2016 results 2,36 
DDD/1000 capita/day, whereas in the Netherlands the 
consumption of this class appeared since in 2001 
around the value 7,02 DDD/1000 capita/day [40]. A 
reason can be the lack of combined schemes of 
therapy and the usage of lower than needed doses. 
These may be indicators of the under-treatment of this 
pathology in our country. 
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In conclusion, the consumption values of anti-
epileptic drugs in Albania are very low. We noted a 
decrease in the consumption of classic antiepileptic 
drugs and a simultaneous increase in the drugs of the 
new generation. Also, an important part of anti-
epileptic drugs flows out of the reimbursement 
scheme.  
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